The phase 2 FENerations1 study is evaluating fenebrutinib dosing in 8 to 12 children and adolescents with relapsing MS with pediatric pharmacokinetic and safety findings not yet reported.
|Slideshows|March 23, 2017
ACC 2017: Late-Breaking Clinical Trials
Author(s)Samantha J. Peterson
Research includes safety of digoxin with atrial fibrillation, comparison of cerebral embolic protection devices, and cerebral microbleed triggers.
Advertisement
Presentations during the Late-Breaking Clinical Trials session at the American College of Cardiology’s Annual Scientific Sessions included a safety investigation of digoxin use in patients with atrial fibrillation, a study of two embolic protection devices and their abilities to prevent stroke and brain infarcts, and possible triggers of cerebral microbleeds during transacatheter aortic valve replacement.
Advertisement
Related to this article
One-year data from the phase 3 AQUARELLE study found that divozilimab, an anti-CD20 antibody, reduced relapse risk in patients with neuromyelitis optica spectrum disorder.
The chief research and medical affairs officer at the National MS Society discussed AI-enabled imaging, biomarkers of progression, women's health across the lifespan, and the Society's Campaign to End MS.
Decade of OPERA Data Supports Early Ocrelizumab Treatment Initiation in Relapsing Multiple Sclerosis
A newly published 10-year analysis of the OPERA I and II trials reported that starting ocrelizumab 2 years earlier was associated with less disability accrual in relapsing MS, with no new safety signals.
Clene has filed an NDA seeking accelerated approval of CNM-Au8 for ALS, following 2 missed primary trial endpoints and years of evolving FDA guidance.
In a 16-person placebo-controlled trial, every cognitively unimpaired adult given AV-1959R developed anti-amyloid-beta antibodies, while placebo recipients stayed at baseline.
Newly presented post hoc analyses examined diazepam nasal spray for status epilepticus in seizure clusters and intervals between clusters in children, alongside real-world data on rescue medication prescribing.
A retrospective 10-center U.S. study found stiripentol reduced convulsive seizure frequency, status epilepticus episodes, and emergency health care use in patients with Dravet syndrome.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Clene Submits NDA Seeking Accelerated Approval for ALS Drug
2
Decade of OPERA Data Supports Early Ocrelizumab Treatment Initiation in Relapsing Multiple Sclerosis
3
First-in-Human Trial Begins for an Antisense Oligonucleotide in KCNT1-Related Epilepsy
4
RGX-202 Meets Primary End Point in Phase 3 Duchenne Trial
5